SIRO Clinpharm appoints chief executive

Takes responsibility for expanding business across the US, Europe and Asia

SIRO Clinpharm, a clinical research organisation headquartered in Mumbai, India has appointed Gopakumar Menon as chief executive to build and enhance the firm’s biopharma service offering, across the US, Europe and Asia.

Menon has been working in the pharmaceutical industry for the more than 12 years in various capacities, from discovery to sales and marketing.

Prior to joining SIRO Clinpharm he worked for Boston, US-based Sciformix. He has had significant experience working with Fortune 500 companies such as Cognizant and Satyam, as well as with venture funded start-up organisations.

SIRO Clinpharm has offices in India, Malaysia, US, Israel Germany, Romania, Estonia, Greece, Czech Republic and Spain.

You may also like

Regulatory

SIRO Clinpharm expands its presence in Asia

Launches operations in Malaysia
Regulatory

SIRO Clinpharm seeks Asia Pacific growth with DreamCIS pact

Mumbai-based contract research organisation SIRO Clinpharm has formed an alliance with DreamCIS, a CRO based in Seoul, South Korea in order to build its business in the Asia Pacific region.
Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP
Manufacturing

AstraZeneca to invest $50 billion in US biopharma innovation and production

Company plans new Virginia manufacturing facility and R&D expansions to meet $80 billion revenue target by 2030
Research & Development

Corteria Pharmaceuticals initiates Phase II trial in heart failure and Phase I trial in obesity

Corteria, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, announces the clinical advancement of its two first-in-class corticotropin‑releasing factor receptor 2 (CRF2) agonists: COR‑1167 and COR‑1389
Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Subscribe now